Targeting Oncogenic RAS With Tri-Complex RAS(ON) Inhibitors

• New Class of Mutant-Targeted Catalytic RAS(ON) Inhibitors
• Exploring strategic combination approaches to amplify efficacy and expand therapeutic reach, building on emerging insights across RAS driven tumor biology
• Showcasing a major year of clinical progress in the field

Speakers:

Helena Kiefel

Senior Director, Translational Research

Revolution Medicines